濮阳东方医院治阳痿技术很不错濮阳东方医院看早泄好不,濮阳东方医院男科治疗早泄怎么样,濮阳东方医院妇科口碑放心很好,濮阳东方收费高不高,濮阳东方医院妇科做人流价格公开,濮阳市东方医院口碑好吗,濮阳东方医院治阳痿价格标准

BEIJING, Oct. 7 (Xinhua) -- Chinese scientists are developing new methods like spraying or dropping hepatitis vaccines into people's noses to replace traditional injections, according to a leading expert on immunology.Such researches were sponsored by a key national science project, according to Wen Yumei, an academician of the Chinese Academy of Engineering, also the chairwoman of the 14th International Symposium on Viral Hepatitis and Liver Disease, which is scheduled to be held in Shanghai next July.At a press conference held here Friday for the symposium, experts believed that broad-coverage inoculations is an effective way in facilitating the country's goal in controlling Hepatitis B.China's Ministry of Health has also credited its national immunization program for having protected about 80 million people from being infected with the Hepatitis B virus (HBV) in the 19 years after 1992.Recent report showed that about 93 million Chinese are HBV carriers, accounting for more than a quarter of the world's total.

OTTAWA, Oct. 26 (Xinhua) -- Canadians are working about three years longer before retirement than they were in the 1990s, and have a longer life in retirement, an official study said Wednesday.Statistics Canada, the federal statistics agency, reports that Canada' s men and women, who don't face compulsory retirement, are increasingly choosing to delay retirement, as part of a long-term trend that has begun before the recent recession.The trend of later retirement dates back to the mid-1990s, when a 50-year-old employee could expect to work another 12.5 years before retiring from the daily grind.Today, that same 50-year-old worker could expect another 16 years of employment.The study says that 34 percent of Canadians aged 55 and older were employed in 2010, compared to just 22 percent in 1996.A longer working life would unnecessarily imply a shorter life in retirement due to increased life expectancy, the study says.The study notes that men and women leaving the work force today are spending as much time in their post-career life as many of their predecessors did.For example, between 1977 and 1994, the typical retirement length for a man in Canada rose from 11.2 to 15.4 years; as of 2008, it was 15 years.For women, the average retirement length similarly rose from 16.4 to 20.6 years between 1977 and 1996; as of 2008, it was 19 years.From another point of observation, 50-year-old men can expect to spend 48 percent of their remaining years of life in retirement in 2008,compared with 45 percent in 1977.In 2008, 50-year-old women could expect to spend 55 percent of their remaining years of life in retirement, nearly identical to the proportion in 1977.

MOSCOW, Oct. 3 (Xinhua) -- A Soyuz-2.1B rocket carried a Glonass-M navigation satellite into orbit early Monday after a two-day delay caused by high winds, a Russian Space Forces spokesman said."The launch of the booster rocket is as scheduled. The satellite Glonass-M was put into the orbit under control at 03:55 Moscow time (2355 GMT on Sunday)," said Colonel Alexei Zolotukhin.Zolotukhin told reporters that the rocket was launched at 0:15 Moscow time (2015 GMT, Sunday) from the Plesetsk Space Center in northern Russia.The Russian Space Forces said the launch was initially scheduled for Saturday but was postponed due to high winds.Glonass is the Russian equivalent of the U.S. Global Positioning System (GPS), which is designed for both military and civilian use. The system requires 24 operational and 2-3 reserve satellites in orbit to ensure global coverage.In December 2010, a malfunction of the booster resulted in a loss of three Glonass satellites.

WASHINGTON, Oct. 9 (Xinhua) -- U.S. researchers have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication Sunday in Nature Biotechnology, researchers describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage."The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, of the Massachusetts General Hospital (MGH) Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes -- an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such as heart disease and cancer."Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. However, the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location.To make sure that their siRNA preparation targeted the right monocytes, researchers first confirmed that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2's usual molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets."These inflammatory monocytes are involved in almost every major disease," Nahrendorf explains. "Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn't affect inflammatory cells that don't rely on the CCR2 receptor. That makes a big difference."

PARIS, Dec. 23 (Xinhua) -- French health authorities on Friday urged 30,000 women to remove the local-made breast implant, pledging that relevant expenses would be covered by the state.The health ministry said in a statement that they spot "no increased risk of cancer currently in women wearing the PIP (Poly Implant Prothese) brand compared with other implants.""However, well-established risks associated with these prostheses are rupture and irritant gel may lead to inflammatory reactions, making it difficult to explant," the statement added.French Health Minister Xavier Bertrand advised French women who have the PIP implants to get them taken out "as a preventive measure but not of an urgent nature." The removal of the implant will be at the state's expense.The recommendation came after eight cases, mainly breast cancer, were reported recently among women with PIP implants.The involved implant was produced by the French company PIP, once the world's third-largest producer of silicone implants who sold its products to tens of thousands of women in more than 65 countries, mainly in South America and western Europe.